dc.contributor.author | RUIZ BAÑOBRE, JUAN | |
dc.contributor.author | Areses Manrique, María Carmen | |
dc.contributor.author | Mosquera-Martinez, J. | |
dc.contributor.author | Cortegoso Mosquera, Alexandra Sabela | |
dc.contributor.author | Afonso-Afonso, F. J. | |
dc.contributor.author | DE DIOS ALVAREZ, NOEMI | |
dc.contributor.author | Fernández Nuñez, Natalia | |
dc.contributor.author | AZPITARTE RAPOSEIRAS, CRISTINA | |
dc.contributor.author | Amenedo, M. | |
dc.contributor.author | Santome, L. | |
dc.contributor.author | Firvida Perez, Jose Luis | |
dc.contributor.author | García Campelo, María del Rosario | |
dc.contributor.author | García González, Jorge José | |
dc.contributor.author | Casal Rubio, Joaquín | |
dc.contributor.author | Vázquez Estévez, Sergio | |
dc.date.accessioned | 2021-11-23T09:14:08Z | |
dc.date.available | 2021-11-23T09:14:08Z | |
dc.date.issued | 2019 | |
dc.identifier.issn | 2218-6751 | |
dc.identifier.other | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6976357/pdf/tlcr-08-06-1078.pdf | es]bi |
dc.identifier.other | https://www.ncbi.nlm.nih.gov/pubmed/32010585 | es]bi |
dc.identifier.uri | http://hdl.handle.net/20.500.11940/15728 | |
dc.description.abstract | The lung immune prognostic index (LIPI) has been proposed as a new categorical blood-based biomarker to select advanced non-small cell lung cancer (NSCLC) patients for anti-programmed cell death-1 (PD-1) or programmed death ligand 1 (PD-L1) therapy. In this study, we investigate for the first time to the best of our knowledge the prognostic and predictive utility of the LIPI in a multicenter nivolumab monotherapy-based cohort. We retrospectively analyzed the influence of the baseline LIPI on overall survival (OS), progression-free survival (PFS), disease control rate (DCR), and overall response rate (ORR) among 153 patients of a cohort of 188 advanced NSCLC patients treated with nivolumab in the second line of therapy or beyond. Worse LIPI was significantly associated with shorter OS in univariate [hazard ratio (HR) =3.12, 95% confidence interval (CI), 2.12-4.60; P<0.0001] and multivariate (HR =3.67, 95% CI, 1.96-6.86; P<0.0001) analyses. Worse LIPI was associated with shorter PFS (HR =1.45, 95% CI, 1.05-2.03; P=0.03), but this correlation did not reach statistical significance in multivariate analysis (HR =1.49, 95% CI, 0.94-2.38; P=0.09). Worse LIPI was associated with lower DCR in univariate [odds ratio (OR) =0.41, 95% CI, 0.24-0.70; P=0.001] and multivariate (OR =0.44, 95% CI, 0.25-0.78; P=0.005) analyses. This study confirms the utility of the LIPI in prognostication and disease control prediction in advanced NSCLC patients treated with nivolumab in the second line of therapy or beyond. | es |
dc.language.iso | eng | es |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International | * |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
dc.title | Evaluation of the lung immune prognostic index in advanced non-small cell lung cancer patients under nivolumab monotherapy | es |
dc.type | Artigo | es |
dc.authorsophos | Ruiz-Banobre, J. | |
dc.authorsophos | Areses-Manrique, M. C. | |
dc.authorsophos | Mosquera-Martinez, J. | |
dc.authorsophos | Cortego, A. | |
dc.authorsophos | Afonso-Afonso, F. J. | |
dc.authorsophos | de Dios-Alvarez, N. | |
dc.authorsophos | Fernandez-Nunez, N. | |
dc.authorsophos | Azpitarte-Raposeiras, C. | |
dc.authorsophos | Amenedo, M. | |
dc.authorsophos | Santome, L. | |
dc.authorsophos | Firvida-Perez, J. L. | |
dc.authorsophos | Garcia-Campelo, R. | |
dc.authorsophos | Garcia-Gonzalez, J. | |
dc.authorsophos | Casal-Rubio, J. | |
dc.authorsophos | Vazquez, S. | |
dc.identifier.doi | 10.21037/tlcr.2019.11.07 | |
dc.identifier.pmid | 32010585 | |
dc.identifier.sophos | 31482 | |
dc.issue.number | 6 | es |
dc.journal.title | Translational lung cancer research | es |
dc.organization | Servizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de Ferrol – Complexo Hospitalario Universitario de Ferrol::Oncoloxía médica | es |
dc.organization | Servizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de A Coruña - Complexo Hospitalario Universitario de A Coruña::Oncoloxía médica | es |
dc.organization | Servizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de Santiago de Compostela - Complexo Hospitalario Universitario de Santiago de Compostela::Oncoloxía médica | es |
dc.organization | Servizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de Ourense, Verín e O Barco de Valdeorras - Complexo Hospitalario Universitario de Ourense::Oncoloxía médica | es |
dc.organization | Servizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de Vigo - Complexo Hospitalario Universitario de Vigo::Oncoloxía médica | es |
dc.organization | Servizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de Lugo, Cervo e Monforte de lemos - Complexo Hospitalario Universitario Lucus Augusti::Oncoloxía médica | es |
dc.organization | Servizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de Pontevedra e O Salnés - Complexo Hospitalario Universitario de Pontevedra::Oncoloxía médica | es |
dc.organization | Servizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS) | es |
dc.page.initial | 1078 | es |
dc.page.final | 1085+ | es |
dc.rights.accessRights | openAccess | es |
dc.subject.keyword | CHUF | es |
dc.subject.keyword | CHUAC | es |
dc.subject.keyword | CHUS | es |
dc.subject.keyword | CHUO | es |
dc.subject.keyword | CHUVI | es |
dc.subject.keyword | HULA | es |
dc.subject.keyword | CHUP | es |
dc.subject.keyword | IDIS | es |
dc.typefides | Artículo Original | es |
dc.typesophos | Artículo Original | es |
dc.volume.number | 8 | es |